Search

Your search keyword '"R. Charles Nichols, MD"' showing total 3 results
Start Over Author "R. Charles Nichols, MD"
3 results on '"R. Charles Nichols, MD"'

1. Consensus Statement on Proton Therapy for Prostate Cancer

Author

Curtis M. Bryant, MD, MPH, Randal H. Henderson, MD, MBA, R. Charles Nichols, MD, William M. Mendenhall, MD, Bradford S. Hoppe, MD, MPH, Carlos E. Vargas, MD, Thomas B. Daniels, MD, C. Richard Choo, MD, Rahul R. Parikh, MD, Huan Giap, MD, PhD, Jerry D. Slater, MD, Neha Vapiwala, MD, William Barrett, MD, Akash Nanda, MD, PhD, Mark V. Mishra, MD, Seungtaek Choi, MD, Jay J. Liao, MD, Nancy P. Mendenhall, MD, and the Genitourinary Subcommittee of the Particle Therapy Co-Operative Group

Subjects
prostate cancer, radiation therapy, proton therapy, particle therapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective studies have been published documenting the efficacy and safety of proton therapy for patients with localized prostate cancer and for patients requiring adjuvant or salvage pelvic radiation after surgery. The Particle Therapy Co-Operative Group (PTCOG) Genitourinary Subcommittee intends to address current proton therapy indications, advantages, disadvantages, and cost effectiveness. We will also discuss the current landscape of clinical trials. This consensus report can be used to guide clinical practice and research directions.

Published
2021
Full Text
View/download PDF

2. Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy

Author

Shivam M. Kharod, MD, Catherine E. Mercado, MD, Christopher G. Morris, MS, Curtis M. Bryant, MD, MPH, Nancy P. Mendenhall, MD, William M. Mendenhall, MD, R. Charles Nichols, MD, Bradford S. Hoppe, MD, MPH, Xiaoying Liang, PhD, Zhong Su, PhD, Zuofeng Li, DSc, and Randal H. Henderson, MD, MBA

Subjects
proton therapy, radiotherapy, prostate cancer, quality of life, Medical physics. Medical radiology. Nuclear medicine, R895-920, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract

Purpose: Postprostatectomy radiation improves disease control, but limited data exist regarding outcomes, toxicities, and patient-reported quality of life with proton therapy. Method and Materials: The first 102 patients who were enrolled on an outcome tracking protocol between 2006 and 2017 and treated with double-scattered proton therapy after prostatectomy were retrospectively reviewed. Eleven (11%) received adjuvant radiation, while 91 (89%) received salvage radiation. Seventy-four received double-scattered proton therapy to the prostate bed only. Twenty-eight received a double-scattered proton therapy prostate-bed boost after prostate-bed and pelvic-node treatment. Eleven adjuvant patients received a median dose of 66.6 GyRBE (range, 66.0–70.2). Ninety-one salvage patients received a median dose of 70.2 GyRBE (range, 66.0–78.0). Forty-five patients received androgen deprivation therapy for a median 9 months (range, 1–30). Toxicities were scored using Common Terminology Criteria for Adverse Events v4.0 criteria, and patient-reported quality-of-life data were reviewed. Results: The median follow-up was 5.5 years (range, 0.8–11.4 years). Five-year biochemical relapse-free and distant metastases-free survival rates were 72% and 91% for adjuvant patients, 57% and 97% for salvage patients, and 57% and 97% overall. Acute and late grade 3 or higher genitourinary toxicity rates were 1% and 7%. No patients had grade 3 or higher gastrointestinal toxicity. Acute and late grade 2 gastrointestinal toxicities were 5% and 2%. The mean values and SDs of the International Prostate Symptom Score, International Index of Erectile Function, and Expanded Prostate Cancer Index Composite bowel function and bother were 7.5 (SD = 5.9), 10.2 (SD = 8.3), 92.8 (SD = 11.1), and 91.2 (SD = 6.4), respectively, at baseline, and 12.1 (SD = 9.1), 10.1 (SD = 6.7), 87.3 (SD = 18), and 86.7 (SD = 13.8) at the 5-year follow-up. Conclusion: High-dose postprostatectomy proton therapy provides effective long-term biochemical control and freedom from metastasis, with low acute and long-term gastrointestinal and genitourinary toxicity.

Published
2021
Full Text
View/download PDF

3. Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408

Author

R. Charles Nichols, MD, Chen Hu, PhD, Jean-Paul Bahary, MD, Kenneth L. Zeitzer, MD, Luis Souhami, MD, Mark H. Leibenhaut, MD, Marvin Rotman, MD, Elizabeth M. Gore, MD, Alexander G. Balogh, MD, David McGowan, MD, Jeff Michalski, MD, Adam Raben, MD, Shari Rudoler, MD, Christopher U. Jones, MD, and Howard Sandler, MD

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objectives: We reviewed testosterone changes for patients who were treated with radiation therapy (RT) alone on NRG oncology RTOG 9408. Methods and materials: Patients (T1b-T2b, prostate-specific antigen

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results